All In Biotech

Drug Trial Radar · NCT02634320

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection

Last checked: Nov 20, 2026Latest source record: Dec 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Dec 2015

Primary completion

Jul 11, 2017

Study completion Jul 11, 2017

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).

Conditions

  • Schizophrenia

Interventions

  • Aripiprazole LauroxilDrug

    Monthly IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Last Treatment Visit in Clinical Global Impressions-Severity (CGI-S) ScoresTime frame: Up to 7 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Little Rock, Arkansas

  • Alkermes Investigational Site

    Rogers, Arkansas

  • Alkermes Investigational Site

    Anaheim, California

  • Alkermes Investigational Site

    Culver City, California

  • Alkermes Investigational Site

    Garden Grove, California

  • Alkermes Investigational Site

    National City, California

  • Alkermes Investigational Site

    Oceanside, California

  • Alkermes Investigational Site

    Orange, California

  • Alkermes Investigational Site

    Panorama City, California

  • Alkermes Investigational Site

    Augusta, Georgia

  • Alkermes Investigational Site

    Chicago, Illinois

  • Alkermes Investigational Site

    Shreveport, Louisiana

  • Alkermes Investigational Site

    St Louis, Missouri

  • Alkermes Investigational Site

    Garfield Heights, Ohio

  • Alkermes Investigational Site

    Lincoln, Rhode Island

  • Alkermes Investigational Site

    Dallas, Texas

  • Alkermes Investigational Site

    Dallas, Texas

  • Alkermes Investigational Site

    DeSoto, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.